Samjin Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1968-04-18
- Employees
- 781
- Market Cap
- -
- Website
- http://www.samjinpharm.co.kr
Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SA001 240mg + Rebamipide 200mg or PlaceboDrug: SA001 480mg or PlaceboDrug: SA001 710mg + Rebamipide 600mg or PlaceboDrug: SA001 1,080mg or PlaceboDrug: SA001 360mg or PlaceboDrug: SA001 720mg or Placebo
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05303961
A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
Phase 4
Completed
- Conditions
- Stroke, Acute
- Interventions
- Drug: Sodium Chloride 45mg/5ml
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 446
- Registration Number
- NCT05301712
- Locations
- 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Chronic Hepatitis b
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 113
- Registration Number
- NCT05286346
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B
Phase 4
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT05282407
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome
Phase 2
Completed
- Conditions
- Primary Sjögren's Syndrome (pSS)
- Interventions
- Drug: SA001 Low doseDrug: SA001 Mid doseDrug: SA001 High doseDrug: Placebo
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05269810
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Clinical Study to Investigate the Efficacy and Safety of SJP002 Ophthalmic Solution in Patients With Dry Eye Syndrome.
Phase 2
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: SJP002 BIDDrug: SJP002 QIDDrug: SJP002 Placebo 1Drug: SJP002 Placebo 2
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT03723811
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.
Phase 2
Completed
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: SA001 High doseDrug: PlaceboDrug: SA001 Mid doseDrug: SA001 Low dose
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 172
- Registration Number
- NCT03723798
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02924155
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SA001 60mg or PlaceboDrug: SA001 240mg or PlaceboDrug: SA001 180mg or PlaceboDrug: SA001 120mg or PlaceboDrug: SA001 300mg or Placebo
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02470286
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath